Join our community of smart investors

Buy Allergy ahead of clinical updates

The allergy specialist has a slew of clinical updates due this year
Buy Allergy ahead of clinical updates

If upcoming results from a Phase III trial of a new birch allergy drug are positive, Allergy Therapeutics’ (AGY) share price could find renewed momentum. The shares lost steam last year after bosses said the results would be delayed, but with data now due in the first quarter of 2019, would-be investors with room for risk in their portfolio could take advantage of the depressed share price.

IC TIP: Buy at 14p
Tip style
Risk rating
Medium Term
Bull points

Strong recent trading 

Upcoming phase three birch results

First human trial for peanut allergy vaccine

Meetings with US regulators

Bear points

Equity fundraising dilution risk

High cash burn

To continue reading...
Join our Community of Smart Investors
  • Independent full-length company analysis
  • Actionable investment ideas and recommendations
  • Expert investment tools and data
  • Stock screens from Algy Hall
Have an account? Sign in